Denis Katz, MD
FDA's response wasn't what they expected: the agency had no established basis for believing that biomarker actually tracked with how patients felt or functioned day to day, and without that link, a clean p-value wasn't going to carry the program. The sponsor had generated rigorous evidence.
https://salienceclinical.com/
Like
Comment
Share
